Roche Kicks Off Review for Xenical Fat Drug

McMains, Andrew
April 2000
Adweek Eastern Edition;4/17/2000, Vol. 41 Issue 16, p4
Reports on Roche Laboratories has launched a review of the Xenical account at Lowe Consumer Healthcare. Creative and media duties in play; Potential side effects of Xenical.


Related Articles

  • Xenical ads lack balance.  // Healthy Weight Journal;May/Jun2000, Vol. 14 Issue 3, p35 

    Deals with the letter made by the United States Food and Drug Administration (FDA) to Hoffman-LaRoche Inc. on the television advertisement of its Xenical or orlistat drug. FDA complaint on the advertisement's imbalances; Action taken by the company on the complaint.

  • Roche sheds Lowe as Xenical agency. Goetzl, David; Snyder Bulik, Beth // Advertising Age;4/17/2000, Vol. 71 Issue 17, p1 

    This article reports on the decision of Hoffman-La Roche to replace the Lowe Group as the advertising agency for weight loss drug Xenical in April 2000. The account for Xenical includes an estimated $80 million direct-to-consumer business as well as physician-targeted advertising. One hurdle...

  • Xenical endures ad silence as FDA forces alterations. Goetzl, David // Advertising Age;11/8/1999, Vol. 70 Issue 46, p40 

    This article reports on the changes made by U.S. drug company Hoffmann-La Roche to the direct-to-consumer advertising campaign for its obesity drug Xenical as of November 1999. The U.S. Food and Drug Administration (FDA) charged the commercial, valued at $70 million to $75 million, lacked fair...

  • FIRST CANADIAN TRIAL FOR XENICAL LAUNCHED.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p5 

    Reports that Hoffman-La Roche Limited has initiated a clinical trial to evaluate its weight loss medication Xenical in Canada.

  • Roche commits $75M to Xenical DTC campaign.  // Drug Store News;11/29/99, Vol. 21 Issue 19, p17 

    Discusses the launching of the television direct-to-consumer (DTC) program for Xenical, one of the largest DTC spends in the industry by Hoffman-La Roche Inc. Overview of the action taken by Hoffman to carry out the program; Role of the Indian Medical Society; Focus of the television campaigns.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Xenical ad campaign planned.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p24 

    Reports on the plans of Roche Laboratories to schedule the follow-up advertising campaign for Xenical. Inclusion of informational advertisements in the introductory campaign; Emphasis of the campaign on the health problem associated with overweight; Presentation on the side effects of the drug.

  • DDMAC: Roche's Tasmar promos mislead.  // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p34 

    Reports on the misleading information presented in the promotional materials for the Tasmar tablets of Roche Laboratories. Failure to include risk information; Assessment of boxed warning; Need for patient monitoring.

  • Roche Kicks Off Review for Xenical. McMains, Andrew // Adweek New England Edition;04/17/2000, Vol. 37 Issue 16, p86 

    Reports on the agency review conducted by pharmaceutical company Roche Laboratories for its Xenical drug advertising account. Concerns over the sales of the drug that fights obesity; Background of the previous advertisement for the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics